Rising Preference for Minimally Invasive Procedures Drives Growth of Embolotherapy Market in North America Patients increasingly prefer minimally invasive surgeries due to their various advantages such as low postoperative pain, less postoperative complications, short hospital stays, and fast recovery times. Trans Arterial Chemo Embolization (TACE) is a minimally invasive procedure that is typically used to treat hepatocellular carcinoma. TACE is used for patients suffering from asymptomatic and unresectable liver cancer. TACE can be used to diminish the size of the tumor and make the patient eligible for liver transplantation. It is considered an evolution from a formerly applied technique called Trans-catheter Arterial Embolization (TAE). Bleeding is a common issue in cancer patients, related to local tumor invasion, tumor angiogenesis, systemic effects of cancer, and anti-cancer treatments. TACE involves a two-step process—selective arterial occlusion restricts the blood supply to the tumor, which causes ischemic tumor necrosis, and regional chemotherapy helps the drug remain in the area for a prolonged period, which starts causing the therapeutic effects. Prostatic artery embolization (PAE) is also a minimally invasive therapy implemented as an elective outpatient technique for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). The number of patients treated with PAE has grown in recent years. Thus, the increasing preference for minimally invasive procedures is fueling the embolotherapy market growth in North America.
Market Overview
The North America embolotherapy market is segmented into the US, Canada, and Mexico. The US held the largest share of the market in 2021, owing to the growing prevalence of hepatocellular cancer and liver cancer coupled with the increasing focus of the major manufacturers on technological advancements. Furthermore, the advanced healthcare sector of the region, the prevalence of sophisticated technological healthcare facilities. The embolotherapy market in the region is anticipated to grow significantly in the coming years owing to the rising cases of brain aneurysms. According to the Brain Aneurysm Foundation’s report, ~6 million people have unruptured brain aneurysms in the US. Also, the annual rate of rupture is nearly 8–10 per 100,000 people; ~30,000 people in the country suffer from a brain aneurysm rupture. In addition, about 4 out of 7 people who recover from a ruptured brain aneurysm are likely to suffer from the disabilities. This neurological disorder generally affects people who are in the age group of 35–60 years. However, the brain aneurysm can also be seen in children, and women in the country suffer more than men.
North America Embolotherapy Market Segmentation
The North America embolotherapy market is segmented on the basis of product, disease indication, procedure, end user, and country.
Based on product, the North America embolotherapy market is bifurcated into embolic agents and support devices. The embolic agents segment held a larger market share in 2022. Based on disease indication, the North America embolotherapy market is segmented into cancer, neurological diseases, urological and nephrological disorders, peripheral vascular diseases, gastrointestinal disorders, and others. The cancer segment held the largest market share in 2022. Based on procedure, the North America embolotherapy market is segmented into transcatheter arterial embolization (TAE), transcatheter arterial radioembolization/selective internal radiation therapy, and transarterial chemoembolization (TACE). The transcatheter arterial embolization (TAE) segment held the largest market share in 2022. Based on end user, the North America embolotherapy market is segmented into hospitals and clinics, ambulatory surgical centers, and other end users. The hospitals and clinics segment held the largest market share in 2022. Based on country, the North America embolotherapy market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022. Abbott Laboratories, Boston Scientific Corporation, Cook Medical LLC, Johnson & Johnson, Medtronic, Acandis GmbH, Balt USA LLC, Stryker Corporation, Guerbet LLC, and Terumo Corporation are among the leading companies operating in the embolotherapy market in North America.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 1,354.02 Million |
| Market Size by 2028 | US$ 2,245.73 Million |
| CAGR (2022 - 2028) | 8.8% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Product
|
|
Regions and Countries Covered
|
|
| North America | US, Canada, Mexico |
| Market leaders and key company profiles |
|
The North America Embolotherapy Market is valued at US$ 1,354.02 Million in 2022, it is projected to reach US$ 2,245.73 Million by 2028.
As per our report North America Embolotherapy Market, the market size is valued at US$ 1,354.02 Million in 2022, projecting it to reach US$ 2,245.73 Million by 2028. This translates to a CAGR of approximately 8.8% during the forecast period.
The North America Embolotherapy Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Embolotherapy Market report:
The North America Embolotherapy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Embolotherapy Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Embolotherapy Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For North America Embolotherapy Market
